. Mapping Pan-Plasmodium and P. falciparum specific primers/probes to consensus sequences of asexual-type 18S rRNAs of major Plasmodium species ..... 5 Figure S2 . Mapping Pan-Plasmodium and P. falciparum specific primers/probes to P. Table S1 . days)] and later thick blood smear (TBS) positive [average 11.2 days (95%CI 9.5-12.8 days)] for a 3.5 day difference (Table S7) . On average, the first malaria-related symptom (any grade) occurred at 9.7 days (95%CI 6.4-13.0 days) and Grade 2 malaria-related symptoms at 12.2 days (95%CI 10.6-13.8 days). RT-PCRestimated parasite densities were similar to TBS-determined densities on the day of patency. Using a modeled treatment threshold of 250 estimated parasites/mL, RT-PCR achieved accelerated infection detection by 2.2 days (95%CI 1.7-2.6 days) versus TBS and 0.7 days (95%CI: -1.4 to 2.7 days) versus malaria-related symptoms. Since subjects were immunologically-naïve, this study did not test for differences in protection by TBS versus biomarker.
MC-003 clinical study
The MC-003 study was a single center, randomized, partially double-blinded, placebocontrolled Phase 1 trial of Infection-Treatment-Vaccination (ITV) using CQ with or without PQ in healthy adult subjects. Vaccinations were followed by five mosquito bite CHMI in all eligible vaccinated and infectivity control subjects. Data was included from CHMI only. Protocol-defined study arms were as follows (total number of subjects that completed CHMI):  Pilot Arm 1a: PQ/CQ ITV three times starting PQ two days post-vaccination (n=2)  Pilot Arm 1b: PQ/CQ ITV three times starting PQ three days post-vaccination (n=2)  Arm 2: PQ/CQ ITV three times starting PQ one day post-vaccination (n=11)  Arm 3: CQ-only ITV three times (n=3)  Arm 4: Drug control treatment with uninfected mosquito bite vaccinations (n=5)  Arm 5: Infectivity controls (n=6) Eighteen vaccinated subjects (Arms 1-3) and 11 control subjects (Arms 4 and 5) underwent CHMI. Upon becoming TBS-positive, subjects were treated with atovaquone/proguanil. Twenty-six of 29 subjects became TBS positive including all control subjects. Amongst Arm 4 and Arm 5 control subjects (n=11), all experienced 1 malaria-related AE post-CHMI, and all became biomarker positive [average 6.9 days (95%CI 6.7-7.1)] before becoming TBS positive [average 9.2 days (95%CI: 8.4-10.0 days)] for a 2.3 day acceleration by RT-PCR (95%CI: 1.5-3.1 days) ( Table S8 ). The first malaria-related symptom of any grade in control participants occurred on average 8.2 days post-CHMI (95%CI: 7.2-9.1 days) and the first Grade 2 malaria-related symptom at 8.8 days (95%CI: 7.9-9.6 days). Using a modeled treatment threshold of 250 estimated parasites/mL, RT-PCR accelerated infection detection by 1.9 days (95%CI 1.2-2.6 days) compared to TBS and 0.9 days (95%CI 0.2-1.6 days) compared to malaria-related symptoms.
Amongst 18 vaccinated participants, both complete and partial protection were demonstrated. Three participants in the PQ/CQ group completely protected against CHMI were excluded from further analysis since there were no positive TBS or biomarker tests for these participants. An additional subject was TBS-positive once and received treatment, but the participant was biomarker-negative and asymptomatic throughout the CHMI --the positive TBS was later deemed a false positive and this subject was excluded from further analysis. Therefore, n=17 vaccinated subjects are included herein. The CQ ITV Arm 3 showed delayed patency in 3/3 participants (TBS positive on days 13-16). Amongst vaccinated participants that eventually became TBS positive (excluding one false positive noted above), 14 subjects became biomarker positive [average 7.5 days (95%CI 6.9-8.1 days)] and later TBS positive days)] for a 3.9 day acceleration by RT-PCR (95%CI: 2.9-4.8 days) ( Table S9 ).
Amongst vaccinees, the first malaria-related symptom of any grade occurred on average 9.8 days post-CHMI (95%CI: 8.5-11.1 days) and the first Grade 2 malariarelated symptom at 10.0 days (95%CI: 8.2-11.8 days). Using a modeled treatment threshold of 250 estimated parasites/mL, RT-PCR accelerated infection detection by 2.6 days (95%CI 1.7-3.5 days) compared to TBS and 1.1 days (95%CI -0.1-2.2 days) compared to malaria-related symptoms.
NIH PfSPZ-CVac PYR study
The NIH Laboratory of Malaria Immunology and Vaccinology (LMIV) PfSPZ-Cvac PYR study (NIAID Protocol 15-I-0169) was a single center, Phase 1 study of ITV consisting of wild-type, aseptic, purified, cryopreserved Pf sporozoites (Sanaria® PfSPZ Challenge) administered by DVI in conjunction with CQ and pyrimethamine (PYR). The pilot and main phases are below with number of enrolled subjects completing CHMI in parentheses:
 Arm 1a (pilot phase) & Arm 2 (main phase): PYR/CQ ITV three times (n=11)  Arm 3: CQ ITV three times (n=5)  Arm 4: Infectivity controls (n=5)
After enrollment and ITV, 21 malaria-naïve healthy adult subjects underwent CHMI with 3200 PfSPZ by DVI (16 vaccinated and 5 infectivity controls). Two positive real time NIH Clinical Center Plasmodium 18S rDNA PCR results on separate days or one positive peripheral TBS were used for initiate treatment with atovaquone/proguanil treatment as in MC-003.
Fifteen of 21 challenged subjects met treatment criteria (TBS-positive and/or NIH PCRpositive), while six vaccinated subjects were completely protected. Of the treated group, six were treated on the basis of positive TBS. Amongst all treated subjects, 12/15 experienced ≥1 AE consistent with malaria infection (including 5/6 TBS-positive subjects).
For analysis, infected subjects were stratified as "TBS-positive" and "all treated". Amongst TBS-positive subjects, 5/6 experienced malaria-related AEs post-CHMI. TBS positivity began on average at 13.5 days (95%CI: 11.0-16.0 days) with RT-PCR becoming positive earlier, on average at day 9.2 post-CHMI (95%CI: 6.1-12.2 days) for a 4.3 day acceleration by RT-PCR (95%CI: 3.1-5.6 days) ( Table S10) . In this group, the first malaria-related symptom of any grade occurred on average at 12.8 days (95%CI: 10.4-15.1 days) and the first Grade 2 malaria-related symptom at 13.8 days (95%CI: 12.2-15.3 days). RT-PCR estimated parasite densities were similar to TBS-determined densities on the day of patency. Using a modeled treatment threshold of 250 estimated parasites/mL, RT-PCR accelerated infection detection by 1.8 days (95%CI: 0.6-3.1 days) compared to TBS and 2.3 days (95%CI: 0.7-3.8 days) compared to symptoms. Amongst all treated subjects, 10/15 subjects experienced one or more malaria-related AEs post-CHMI. Fifteen subjects who were treated [average 12.0 days (95%CI: 10.8-13.2 days)] became biomarker positive on average at 8.6 days (95%CI: 7.6-9.6 days) ( Table S11 ). The first malaria-related symptom of any grade occurred on average at 11.3 days post-CHMI (95%CI: 9.6-13.0 days) and the first Grade 2 malaria-related symptom on 13.5 days (95%CI: 11.9-15.1 days). At a modeled treatment threshold of 250 estimated parasites/mL, RT-PCR detected infections 2.7 days before symptom onset.
When protective efficacy was evaluated by vaccination arms, partial protection was best associated with the time to first positive biomarker 250 estimated parasites/mL although the association did not reach statistical significance because of the limited number of subjects available. The first day of positive RT-PCR and the density of the first positive result were not statistically associated with delayed TBS positivity except when TBS patency was delayed to Day 13 or later. Six subjects were completely protected and showed complete biomarker and TBS agreement. Overall, the 18S rRNA biomarker outperformed TBS for infection detection in the six TBS-positive subjects and confirmed complete protection in all TBS-negative participants. Figure S1 . Pan-Plasmodium and P. falciparum specific primers/probes aligned to consensus sequences of asexual-type 18S rRNAs of major Plasmodium species Alignment of partial reference sequences for A-type 18S rRNA genes of P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi across the pan-Plasmodium and P. falciparum-specific amplicon region with primers and probes. Asterisks indicate 100% conserved sequences for all sequences shown. Solid green fill indicates the position of forward and reverse pan-Plasmodium primers and green text indicates the position of the corresponding probe (with corresponding labels). Solid red fill indicates the position of forward and reverse P. falciparum-specific primers and red text indicates the position of the corresponding probe (with corresponding labels). Figure S2 . Pan-Plasmodium and P. falciparum specific primers/probes alignment to P. falciparum sexual-and asexual-type 18S rRNAs sequences Partial reference sequences for the two A-type (PF3D7_0513600 and PF3D7_0725600) and two S-type (PF3D7_0112300 and PF3D7_1148600) 18S rRNA genes of Pf aligned to the pan-Plasmodium and Pf-specific primers and probes. Asterisks represent sequences conserved across all species. Solid green and red fill indicate the positions of pan-Plasmodium and Pf-specific reagents (with corresponding labels) as in Figure  S1 . Figure S3 . Bland-Altman difference plots for P. falciparum (A) and panPlasmodium (B) qRT-PCR Samples ranging from 1x10 2 parasites/mL to 4x10 5 parasites/mL (relevant range for CHMI studies) were tested for biomarker-based differences (bias) from known (nominal) densities. qRT-PCR data are presented as log10 parasites/mL. This data supports the decision to quantify using the pan-Plasmodium channel since this channel had the least average and concentration-dependent bias across this range of parasite densities. a There were 1 bp substitutions in each of the probe and reverse primer sequence that occurred in 1/19 P. vivax sequences. The substitutions occurred in the same sequence (DQ660817.1) and this sequence was A-type but divergent from the other 18 available P. vivax sequences. b Two P. ovale wallikeri sequences align to A-type genes more than S-type genes but diverge from the 11 other P. ovale wallikeri and 7 P. ovale custisi A-type sequences and were considered outliers. Precision calculations used log10 copies/mL of blood values in accordance with FDA biomarker qualification guidance. TBS, thick blood smear; N, number of volunteers; NA, not applicable *Definition of infection described in the study protocol. 
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